A positive CMV IgG test means your immune system has encountered cytomegalovirus (CMV) at some point and built lasting antibodies against it. It does not mean you are currently sick, and in the vast majority of cases it reflects an infection that came and went without you ever noticing. Globally, roughly 83% of people carry these antibodies, though the rate varies widely by region and age. The result raises different questions depending on your situation, particularly if you are pregnant, preparing for organ transplantation, or living with a compromised immune system.
How Common CMV Infection Really Is
CMV is one of the most widespread viruses on the planet. A large systematic review and meta-analysis estimated global seroprevalence at about 83% in the general population and 86% among women of childbearing age, with the highest rates in the Eastern Mediterranean region (around 90%) and the lowest in Europe (around 66%).1PubMed. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis Among women of reproductive age specifically, seroprevalence ranged from under 25% in some North American populations to over 95% in parts of Latin America and Europe.2PubMed Central. A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development In a recent Korean cross-sectional study, overall seropositivity was about 90%, climbing from 76% in the 20–29 age group to nearly 100% in adults aged 50–59.3Annals of Laboratory Medicine. Recent Trends in Cytomegalovirus IgG Seropositivity in the Adult Population of Korea: A Cross-Sectional Study and Literature Review
The pattern across all these studies is consistent: rates climb with age, are higher in developing countries, and correlate with socioeconomic factors. If your test came back positive, you are in the majority worldwide. The question that actually matters is what that positive result means for your particular health situation.
Why the Virus Stays With You for Life
CMV belongs to the herpesvirus family, and like its relatives (the viruses behind cold sores and chickenpox), it never fully leaves. After the initial infection, the virus tucks itself into certain bone marrow cells, specifically myeloid progenitor cells, and stays there in a dormant state.4PubMed. Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells Research has shown that even more primitive blood-forming stem cells can harbor the virus and pass it along as they mature into immune cells.5PubMed. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells
Your immune system keeps the virus in check through constant surveillance. The IgG antibodies your test detected are part of that surveillance team, but they are far from the whole story. T cells and other immune mechanisms do much of the heavy lifting. In a healthy person, this arrangement works well enough that you never feel it. The virus reactivates periodically at low levels, sometimes shedding in saliva or urine without causing symptoms. The trouble comes when immune defenses weaken, whether from medication, disease, or transplant conditioning regimens. That is when dormant CMV can flare into active, symptomatic infection.
IgG Versus IgM and What Each Tells Your Doctor
Most CMV blood panels report both IgG and IgM antibody results. They answer different questions. IgG antibodies develop within a few weeks of first exposure and persist for life. IgM antibodies are typically the first to appear during a new infection and are supposed to fade within a few months. So in textbook terms, IgG-positive alone means a past infection, while IgG-positive plus IgM-positive raises the possibility that the infection is recent.
The reality is messier. In a study of patients with CMV mononucleosis, most antibody classes dropped to borderline or undetectable levels within two months after symptoms, except for IgG, which stayed positive long-term.6PubMed Central. Kinetics of specific immunoglobulins M, E, A, and G in congenital, primary, and secondary cytomegalovirus infection studied by antibody-capture enzyme-linked immunosorbent assay But IgM is not always a reliable marker of recent infection. It can pop up again during viral reactivation in someone who was infected years ago, and it sometimes lingers for months after the initial infection is over.7PubMed Central. Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy On top of that, cross-reactivity can cloud the picture. Testing on the Architect platform showed that samples positive for other infections, including Epstein-Barr virus, hepatitis A, and rubella, sometimes triggered false-positive CMV IgM results.8Journal of Laboratory Medicine and Quality Assurance. Cross-Reactivity of Disease-Specific Antibody Assays for the Detection of Current Infections: With Potentially Interfering Substances of Other Infections
All of this means that a positive IgG with a positive IgM does not automatically indicate a brand-new CMV infection. Your doctor may need additional testing to sort out the timing, which is where avidity testing comes in.
How Avidity Testing Pins Down the Timing
IgG avidity refers to how tightly IgG antibodies bind to the virus. Early after a first infection, your immune system produces antibodies that latch on relatively loosely. Over the following months, those antibodies mature and grip the viral targets much more firmly. Measuring that grip strength helps distinguish a recent first-time infection from one that happened long ago.
Two decades of research have established IgG avidity as a reliable tool for this purpose. Low avidity points to a primary infection within the preceding three to four months, while high avidity effectively rules out a first infection in the previous three months.7PubMed Central. Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy In one study of pregnant women, an avidity index above 65% strongly suggested a past infection, whereas an index below 50% corresponded to a recent primary infection.9PubMed. Avidity of IgG antibodies distinguishes primary from non-primary cytomegalovirus infection in pregnant women
Avidity testing is most useful when both IgG and IgM come back positive and the clinical stakes are high. If you are already IgG-positive with high avidity and no IgM, a doctor can be confident the infection happened well before any current pregnancy or transplant planning window.
What a Positive Result Means During Pregnancy
Pregnancy is the context where CMV IgG results cause the most anxiety, and rightfully so. CMV is the most common congenital viral infection worldwide, and in-utero transmission can lead to hearing loss, developmental delay, and other serious problems in the baby. But the risk is not the same for every pregnant person who tests IgG-positive.
The critical distinction is between a primary (first-time) infection during pregnancy and what researchers call non-primary infection, which includes reactivation of an old infection or catching a new strain. Primary infection during pregnancy carries a 30% to 40% chance of the virus crossing the placenta and reaching the fetus. In contrast, mothers who were already seropositive before conception and experienced reactivation or reinfection face a much lower risk of passing it along, estimated at roughly 0.2% to 2%.10PubMed Central. Cytomegalovirus Infection in Pregnancy: Should All Women Be Screened? One prospective study found that no woman with confirmed non-primary infection transmitted the virus to her fetus at all.11PubMed. Human cytomegalovirus non-primary infection during pregnancy: antibody response, risk factors and newborn outcome
So if you were already IgG-positive before you became pregnant, or if your positive IgG result is paired with high avidity indicating a long-standing infection, the risk to your baby is substantially lower than in someone catching CMV for the first time during pregnancy. That said, “lower risk” is not “zero risk.” Pre-existing immunity is protective but not airtight, because CMV has multiple strains, and reinfection with a different strain remains possible. Women who spend a lot of time around young children, who tend to shed CMV in saliva and urine, may be exposed to new strains more frequently.12PubMed Central. Repeated measures study of weekly and daily cytomegalovirus shedding patterns in saliva and urine of healthy cytomegalovirus-seropositive children
Reducing Exposure Through Hygiene
Whether you are IgG-negative and want to stay that way during pregnancy, or IgG-positive and hoping to avoid reinfection with a new strain, behavioral measures can help. Young children, especially those in daycare, are the primary source of CMV transmission to adults. A molecular epidemiology study demonstrated that CMV strains passed readily from children in daycare to their parents and caretakers, with six of eighteen seronegative mothers acquiring the virus within months of their children’s infections.13PubMed. Molecular epidemiology of cytomegalovirus: viral transmission among children attending a day care center, their parents, and caretakers
The preventive advice is straightforward: wash your hands after changing diapers, avoid sharing utensils or cups with toddlers, and do not kiss young children on the mouth. The American College of Obstetricians and Gynecologists recommends that physicians counsel pregnant women about these hygiene measures.14PubMed Central. Washing our hands of the congenital cytomegalovirus disease epidemic A systematic review of hygiene-based interventions found that they do reduce CMV acquisition during pregnancy to some extent, though perfect compliance is difficult in real life, especially for parents of toddlers.15PubMed Central. Hygiene-based measures for the prevention of cytomegalovirus infection in pregnant women: a systematic review
Why CMV Status Matters Before a Transplant
Outside of pregnancy, the medical scenario where CMV IgG status matters most is organ and stem cell transplantation. Before any transplant, both the donor and recipient are tested for CMV IgG. The riskiest combination is a seronegative recipient receiving an organ from a seropositive donor. In that scenario, the donor’s latent CMV can reactivate inside the recipient, whose immune system has never encountered the virus and is simultaneously being suppressed by anti-rejection medications.16PubMed Central. Cytomegalovirus infection in transplant recipients
If you are IgG-positive going into a transplant, it tells the medical team that you carry latent virus that could reactivate when immunosuppressive drugs weaken your defenses. You may be placed on antiviral prophylaxis or monitored regularly with viral-load blood tests. The knowledge that you are seropositive is not bad news per se; it simply shapes the prevention strategy.
CMV and HIV
People living with HIV have historically faced serious CMV complications. Before effective antiretroviral therapy, CMV retinitis was a leading cause of blindness in people with advanced AIDS. Antiretroviral treatment dramatically changed the landscape. A study covering the combination antiretroviral therapy era found CMV infection occurred at a rate of about 1.7 cases per 1,000 person-years among HIV-positive patients, and no cases presented with eye disease, suggesting that effective HIV treatment keeps CMV reactivation largely in check.17PubMed Central. Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy Still, the 30-day mortality rate of 18% among those who did develop CMV disease underlines that reactivation in this population remains dangerous when it happens.
For someone with well-controlled HIV, a positive CMV IgG result carries roughly the same implications as for the general population: you have past infection, you carry the virus, and keeping your immune system healthy is the best defense against reactivation.
When Higher Antibody Levels Raise Questions
Most routine CMV IgG tests give a simple positive or negative result, or a number above or below a cutoff. But some clinicians pay attention to just how high the IgG level is, because an unusually elevated titer may reflect ongoing immune stimulation rather than quiet latency. In one study of patients with cardiovascular risk factors, those with the highest anti-CMV IgG titers (1:800 or above) were disproportionately represented among people with active coronary disease and restenosis after angioplasty, while seropositive controls had titers no higher than 1:400.18PubMed. Anti-cytomegalovirus (CMV) IgG antibody titer in patients with risk factors to atherosclerosis
A separate study in HIV-positive individuals on suppressive antiretroviral therapy found that those in the highest quartile of CMV IgG levels had roughly 2.4 times the odds of experiencing non-AIDS-related health events compared to those in the lowest quartile.19PubMed Central. Increased CMV IgG Antibody Titer is Associated with Non-AIDS Events among Virologically Suppressed HIV-Positive Persons These are associations, not proof that the antibodies themselves cause disease. The thinking is that a very high titer may signal that the immune system is working harder than usual to contain CMV, producing low-grade chronic inflammation in the process. Whether reducing that inflammation through antiviral therapy would improve outcomes is still an open question.
CMV, Aging, and the Immune System
Researchers have been exploring a connection between lifelong CMV infection and the gradual weakening of the immune system that comes with age, a process sometimes called immunosenescence. The hypothesis is that decades of keeping CMV in check gradually reshapes the immune system, diverting resources toward CMV-specific cells at the expense of broader immune flexibility. Multiple studies have linked CMV seropositivity or elevated CMV antibody levels with cardiovascular disease, neurocognitive decline, dementia, and frailty in older adults.20The Journal of Infectious Diseases. Cytomegalovirus and Aging—How Can the Field Move Forward?
A review in the International Journal of Molecular Sciences explored how chronic CMV infection shifts the composition and function of immune cell populations over a lifetime, potentially contributing to age-related conditions including cancer and neurodegenerative disease.21PubMed Central. Immunosenescence and Cytomegalovirus: Exploring Their Connection in the Context of Aging, Health, and Disease This is a genuinely active area of research, not settled science. Most of the evidence is observational, meaning researchers have found that CMV-positive older adults tend to have certain health issues more often than CMV-negative ones, but disentangling CMV’s role from all the other factors that affect aging is extremely difficult. Still, the fact that this research keeps accumulating suggests CMV is more than an innocent bystander in the aging process.
For a healthy person reading their lab results, this does not mean a positive IgG is cause for alarm. Billions of people carry CMV with no obvious health consequences. But it does offer a glimpse into why some researchers consider CMV more than a trivial childhood infection.
Where Vaccine Development Stands
There is currently no approved vaccine against CMV, despite decades of effort. The virus has been on public health priority lists for years because of the burden of congenital infection alone. A glycoprotein B (gB) vaccine showed some ability to prevent infection in young women and in CMV-seronegative organ transplant recipients, which energized the field even though it was only partially effective.22Journal of Virus Eradication. Cytomegalovirus vaccines under clinical development Several newer candidates are under study, and a consensus statement from a recent expert meeting noted that a safe and effective CMV vaccine now seems within reach, with even a partially effective vaccine expected to significantly reduce the global health impact.23PubMed Central. A vaccine against cytomegalovirus: how close are we?
A vaccine would be most valuable for seronegative women before pregnancy and for seronegative transplant recipients, since those are the groups facing the highest risks from a first CMV encounter. For people who are already IgG-positive, a therapeutic vaccine designed to boost immune control of latent virus is a more distant prospect, but one that researchers are interested in given the immunosenescence data discussed above.
How CMV Has Learned to Coexist With Us
CMV has co-evolved with humans over millions of years, developing an unusually large and sophisticated toolkit for dodging the immune system. Its genome is one of the biggest among human viruses, and a substantial portion of that genetic real estate is devoted to immune evasion. The virus can downregulate the molecules that immune cells use to detect infected cells, interfere with inflammatory signaling, and hide inside the very immune cells tasked with finding it.24PubMed Central. Battle between Host Immune Cellular Responses and HCMV Immune Evasion This is why it achieves lifelong latency so successfully and why building an effective vaccine has been so challenging.
From an evolutionary standpoint, CMV’s strategy has been spectacularly successful. The virus persists in the vast majority of the human population, rarely kills its host, and transmits efficiently through saliva, urine, breast milk, and sexual contact. The price we pay for this cohabitation is mostly invisible in day-to-day life, but it surfaces in the specific clinical situations covered throughout this article: pregnancy, transplantation, immunosuppression, and possibly the slow reshaping of our immune systems as we age.